Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
about
Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistanceChanges in body weight and psychotropic drugs: a systematic synthesis of the literaturePredictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health AdministrationInflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.Treatment-resistant depression in primary care across CanadaH1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Treating bipolar disorder. Evidence-based guidelines for family medicine.Almost all antipsychotics result in weight gain: a meta-analysis.Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.Pharmacotherapy to limit weight gain caused by antipsychotic use.Atypical antipsychotics and diabetes mellitus.Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.Desipramine inhibits histamine H1 receptor-induced Ca2+ signaling in rat hypothalamic cells.Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studiesMetabolic side effects of atypical antipsychotics in children: a literature review.Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring.Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.Phentermine, sibutramine and affective disorders.Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settingsIdentification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics.Effectiveness of a psychosocial weight management program for individuals with schizophreniaPsychiatric treatment: A risk factor for obesity?Alterations of Lipid-Lipoprotein and Leptin in Bipolar Disorder Associated with Clinic Process.Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication.The impact of weight gain associated with atypical antipsychotic use in schizophrenia.Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies.Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.Prevalence of Antidiabetic and Antilipidemic Medications in Children and Adolescents Treated With Atypical Antipsychotics in a Virginia Medicaid Population.Blood lactate levels as a biomarker of antipsychotic side effects in patients with schizophrenia.Antipsychotic drugs and diabetes.Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study.Characterization of olanzapine-induced weight gain in rats.Weight change after an atypical antipsychotic switch.Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications.Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin.Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.
P2860
Q27323282-722BEE14-28EC-4068-A929-1631128EE4E4Q28728401-52438A73-2A11-4ECC-B734-7C37E592B327Q33519730-8436066E-4608-4B7D-AB7F-E9E191C2EEFEQ33721019-3F63FE5B-E644-4A4C-932D-249534E6D1B1Q33861601-EE445B2C-FB0A-48A2-9EBD-E5100ABD3324Q33964839-84ACC45E-3EA2-49B7-ADCC-DD1F5A1DEEBAQ34550254-F11E31B6-99B4-4077-A31E-987A9A7768D4Q34661499-D6AA25D8-2E77-4CB6-B330-4A66730E4FF4Q35100107-45D2DA8F-2AB2-414C-AC27-96AF85BB55D2Q35548146-0A06D8C8-65EF-462D-9566-A688B51326D4Q35793345-BFCEE123-17EB-4C13-98B8-3C2B0A23EE35Q35826319-27138579-21CF-47A3-A10A-6D2A3B4D240AQ35918173-8D03EF42-8869-4F7B-9F77-0CB770A7F932Q36205791-48044093-3CA7-4924-A38C-76222AABA198Q36230583-596DD3F4-E1B0-4C2D-A785-CD049C1D9F6CQ36258561-08380CA9-6304-48FC-96BF-1D132CA7AD9BQ36302677-A0B51436-8540-4CB2-A4BD-0BF4587C8A67Q36377890-AAB4B3E9-B0BF-4CAC-A2B8-4481811544BCQ36832356-DDB9FF1C-DF08-4DE2-B906-75D3DE6C5941Q36836820-17E4B990-E47E-463C-9E86-FB59948F58BFQ37147674-EEA48109-3A99-4C90-821C-E165CF2C981FQ37155311-52B4972E-9F74-40DE-AFA1-6C8786ABBD91Q37257633-1621A319-7B11-4369-A4B7-50D6A24C4981Q37479172-00D9F50E-906B-44E6-BC28-B2421B0E6F55Q37725872-1A968BED-42B6-4EAA-ADB4-93A808C45213Q37958894-5BB546B1-0E71-4CE9-9D3D-37A060448484Q38050714-7480CA05-3FFF-4A75-99DB-E61ED364467FQ38777526-DC0D260F-33EB-4E08-94AC-F7A067C78B91Q39353717-46BBA09B-5EF4-41EB-963C-05874B85AF67Q39675765-6B8A682E-4543-49B2-B91D-674936F050FCQ40836016-3023575C-232F-49D0-8699-578EDAD7C5D6Q41118477-E52B7C0D-AFE8-4D91-B544-7884435BFAF8Q42864443-25AE76BE-144E-46C0-9513-0B90A4AA0A12Q44103185-13C53054-A48C-4DA0-BB04-62A5AC252AAAQ44263522-1B08DC34-55E8-480B-BB04-003C4FC3974AQ44602396-6B1B82DB-661D-445E-8C77-ACADC7860365Q44858920-20264F44-8D14-4CBF-8E16-5296841A45C6Q45053023-3439CC53-E2C5-4798-910D-4B23434D2B5CQ46070377-351D3501-CFD1-4845-A4E0-62B89C3BE675Q46735466-F9E5CCF8-5B8D-4317-9A4A-ED46D39823AD
P2860
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@ast
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@en
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@nl
type
label
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@ast
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@en
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@nl
prefLabel
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@ast
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@en
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@nl
P2093
P2860
P1476
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
@en
P2093
R S McIntyre
S H Kennedy
S M McCann
P2860
P304
P356
10.1177/070674370104600308
P407
P577
2001-04-01T00:00:00Z